Greenwich LifeSciences (NASDAQ:GLSI) Cut to “Sell” at Wall Street Zen

Greenwich LifeSciences (NASDAQ:GLSI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. HC Wainwright upped their target price on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Greenwich LifeSciences currently has a consensus rating of “Hold” and a consensus price target of $47.50.

Greenwich LifeSciences Stock Performance

GLSI opened at $24.21 on Friday. The stock has a market capitalization of $335.31 million, a P/E ratio of -16.58 and a beta of 1.53. The company’s 50-day simple moving average is $25.31 and its two-hundred day simple moving average is $19.19. Greenwich LifeSciences has a 52-week low of $7.78 and a 52-week high of $34.10.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Greenwich LifeSciences by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after acquiring an additional 13,179 shares during the period. Geode Capital Management LLC raised its stake in Greenwich LifeSciences by 6.7% during the 4th quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock worth $3,187,000 after acquiring an additional 9,568 shares during the period. State Street Corp raised its stake in Greenwich LifeSciences by 19.3% during the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after acquiring an additional 15,831 shares during the period. Marshall Wace LLP bought a new stake in Greenwich LifeSciences during the 2nd quarter worth approximately $509,000. Finally, Virtu Financial LLC bought a new stake in Greenwich LifeSciences during the 4th quarter worth approximately $605,000. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.